Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, John M. Russell et al.|The Lancet|2015Cited by 2k
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, Melissa Spears et al.|Annals of Oncology|2018Cited by 252
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth Woods, Mark Sculpher, E.G. Sideris et al.|European Urology Oncology|2018Cited by 27
Optimal management of radiation pneumonitis: Findings of an international Delphi consensus studyIndu S. Voruganti Maddali, Alexander V. Louie, Cicely Cunningham et al.|Lung Cancer|2024Cited by 20